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Summary  The  ability  to  predict  and  then  mitigate  potential  health  effects  is  crucial  for  sus-
tainability of  nanotechnology,  yet  approaches  to  testing  must  evolve  to  provide  both  specificity
and efficiency  whilst  reducing  the  burden  of  animal  testing.  To  provide  risk  assessment  with
adequate information,  a  complementary  strategy  relying  on  the  use  of  exposure  biomarkers  can
be envisaged  as  part  of  a  holistic  approach  to  supporting  effective  risks  management  systems.Risk  assessment Candidate  biomarkers  should  be  further  validated  in  controlled  human  studies.  This  article  dis-
cusses the  meaning  and  role  of  biomonitoring  as  key  component  of  a  comprehensive  toolbox  of
nanosafety.Please  cite  this  article  in  press  as:  E.  
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Nano-objects,  including  their  aggregates  and  agglomer-
tes  (NOAA)  [1,2]  are  increasingly  being  brought  to  the
ommercial  market  as  a  key  to  industrial  innovation  in  many
elds.  Increased  availability  and  use  of  NOAA  brings  with
t  innovative  applications  but  also  the  possibility  of  per-
onal  exposure  with  potentially  unwanted  health  effects;
 key  concern  for  the  long-term  sustainability  of  nanotech-
ology.  Engineered  nano  materials  (ENM)  have  not  yet  been
eported  to  cause  health  effects  in  humans;  however,  there
s  accumulating  evidence  from  animal  studies  supporting
he  concern  that  exposure  to  some  nanomaterials  could  be
armful.  As  a  result,  ensuring  the  safety  of  nano-enabled
roducts  is  seen  as  a  crucial  element  in  full  exploitation  of
he  benefits  of  nanotechnology  [3,4].
The  existing  framework  for  risk  assessment  (RA)  of  ENM
as  substantial  limitations  in  supporting  the  health  impact
ssessment  of  this  new  class  of  chemicals.  The  ‘‘Strategic
esearch  Agenda  towards  Safe  and  Sustainable  Nanoma-
erial  and  Nanotechnology  Innovations’’  [5]  released  by
he  NanoSafety  Cluster  —  an  EU  Commission  initiative
o  maximize  the  synergies  between  the  existing  projects
ddressing  all  aspects  of  nanosafety  —  recognizes  that
he  conventional  RA  framework  may  fail  to  fully  estimate
he  risks  from  ENM  due  to  methodological  limitations  and
nowledge  uncertainties.
Accurate  assessment  of  health  risk  of  ENM  requires  infor-
ation  on  target  organs  of  ENM  toxicity  and  knowledge  of
elevant  endpoints  gathered  from  studies  in  which  expo-
ures  have  been  well  characterized.  Screening  strategies
onsisting  of  in  vitro  and  in  vivo  assays  have  been  devel-
ped  for  increasing  the  rate  of  hazard  identification  [6—8].
o  support  this,  high-throughput  and  high-content  screening
7]  along  with  the  alternative  test  strategies  [8]  have  been
nvisaged  as  powerful  tools  to  expedite  the  pace  of  haz-
rd  identification  and  RA.  The  data  generated  by  these
pproaches  will  certainly  improve  safety  assessment,  yet
he  complex  and  multi-faceted  nature  of  events  occurring  at
he  nano-bio  interfaces  means  that  the  full  replacement  of
n  vivo  assessment  is  not  yet  possible.  Moreover,  the  nature
f  these  interactions  is  complex,  changeable  and  the  bio-
ogical  behaviour  of  ENM  is  not  yet  predictable  solely  on
he  basis  of  size,  shape  and  surface  chemistry,  since  these
nherent  properties  are  subject  to  change  in  response  to  bio-
ogical  environment.  Therefore,  toxicological  testing  should
e  seen  as  a  spectrum  where  the  further  we  get  from  humans
y  using  increasingly  simplified  models,  more  caution  should
e  exercised  in  the  interpretation  of  findings.  To  overcome
ncertainties  due  to  the  inherent  limitations  of  simplified
odels,  a  complementary  strategy  facing  the  need  to  assess
he  health  impact  of  nanotechnology  in  those  potentially
xposed  is  proposed  [4,9]  and  a  key  component  of  this  is
he  application  of  biological  monitoring  (BM).
BM  is  used  in  occupational  and  environmental  health  to
dentify  potential  hazards  of  new  and  emerging  chemicals
nd  monitor  groups  at  risk  of  health  outcomes.  The  main
bjectives  of  BM  [10]  are:  (i)  assessment  of  individual  or
roup  exposure;  (ii)  identification  of  early  (preferably  spe-
ific)  effects  which  are  indicative  of  an  actual  or  potentialPlease  cite  this  article  in  press  as:  E.  
http://dx.doi.org/10.1016/j.nantod.2015.02.001
ealth  effects,  and,  ultimately,  (iii)  assessment  of  health
isk  to  exposed  subjects.
Biomarkers  are  measurable  or  observable  parameters
hat  reveal  designated  events  in  a  biological  system  and
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re  useful  in  assessing  the  effects  or  exposure  to  harmful
ubstances,  especially  where  there  are  low  or  intermittent
evels  of  exposures,  mixtures  of  toxicants  that  may  act
ynergistically,  or  exposure  resulting  in  disease  with  long
atency  period.  Since  biomarkers  are  ideally  directly  related
o  the  adverse  effects  which  one  attempts  to  prevent,  the
se  of  BM  represents  an  essential  tool  in  health  RA  [10].
owever,  a  major  challenge  is  the  specificity  of  biomarkers
long  with  the  health  significance  of  the  observed  changes.
The  issue  of  (nano)specificity  of  biomarkers  is  challenging
ecause  the  reduction  in  size  of  particles  to  the  nanoscale
s  believed  to  drive  new  and  unpredictable  effects  meaning
hat  a  robust  knowledge  of  toxicological  properties  of  cer-
ain  nanoparticles  is  not  yet  apparent  and  may  not  be  confi-
ently  inferred  from  bulk  particles  of  the  same  composition.
owever,  evidence  thus  far  from  conventional  particles,  sug-
ests  similar  paradigms  of  particle  and  nanoparticles  toxicity
11]  such  as  the  role  of  shape,  surface  area,  presence  of
eactive  transition  metals.  Therefore  within  the  hierarchy  of
iomarker  development  (Fig.  1),  an  efficient  approach  is  to
raw  exploratory  and  candidate  biomarkers  from  other  fields
f  particle  toxicology,  in  particular  air  pollution  studies.
his  is  because  in  real  exposure  scenarios,  ENM  share  some
haracteristics  with  combustion-derived  ultrafine  particles
nd  these  similarities  could  drive  the  knowledge-based  data
o  select  high  value  biomarkers  [12]. Biomarkers  of  expo-
ure  and  effect  are  potentially  available  because  a  panel  of
arameters  indicative  of  local  or  systemic  inflammation  and
xidative  damage  has  been  validated  in  air  pollution  studies
13,14].  Limited  field  studies  have  applied  such  biomarkers
n  exposed  workers  [15—17]  yet  some  of  these  suffer  from  a
ack  of  quantitative  exposure  assessment  and  characteriza-
ion  to  both  ENM  and  environmental  background  which  limit
he  validation  of  biomarkers  against  exposure  levels.
As  with  conventional  particles,  the  nanoparticle  surface
orms  the  point  of  contact  with  cells  therefore  surface
rea  and  surface  chemistry  are  important  determinants  of
anoparticle  interaction  with  biological  systems  [18,19]  and
oxicity  [20].  However  the  chemical  identity  of  particles  can
e  further  modified  after  contact  with  biological  fluids  such
s  lung  lining  fluid  or  blood  due  to  binding  of  biomolecules,
uch  as  proteins  and  lipids,  to  form  a  corona  that  interacts
ith  biological  systems  [21]. Moreover,  besides  the  inher-
nt  properties  of  the  material,  the  capacity  of  ENM  to  act
s  vectors  for  the  transport  of  other  toxic  chemicals  to
ensitive  tissues  (Trojan  horse  effects)  should  be  consid-
red  [22].  Such  alterations  in  surface  characteristics  are
n  important  experimental  consideration  yet  toxicologists
ften  try  to  understand  the  toxicological  profile  of  ENM  by
hallenging  their  experimental  systems  with  clean  —  but
ot  naked  —  particles  which  may  not  be  truly  represen-
ative  of  particle—cell  interactions  in  a  real-life  scenario.
his  latter  point  adds  to  the  artificiality  of  laboratory  based
esting  yet  the  issue  of  truly  representing  real  life  scenar-
os  is  challenging.  When  considering  the  harmful  effects
f  particles  in  occupational/environmental  settings,  these
re  consistently  associated  with  a  multiplicity  of  factors,
ncluding  changes  occurring  at  the  surface  of  nanoparti-Bergamaschi,  et  al.,  Nano  Today  (2015),
les.  Agglomeration/aggregation  of  nanoparticles  in  contact
ith  biological  media  represent  a  critical  issue  in  laboratory
xperiments  affecting  the  actual  dose  delivered  to  the  sys-
em  (in  vitro) [23]  and  the  dose  at  the  target  sites  (in  vivo).
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Figure  1  Layout  of  biomarkers  research  as  condition  of  the  responsible  development  of  nanotechnologies  and  safety  of  workers
exposed to  engineered  nanomaterials  (ENM).  With  the  advancement  of  the  knowledge  about  the  interaction  between  ENM  and
biological systems,  the  relevance  of  the  toxicology  data  to  humans  should  be  considered.  Advances  in  ‘‘-omic’’  techniques  and
systems toxicology  can  provide  information  on  whether  specific  biological  pathways  are  activated/perturbed,  thus  identifying
fingerprints and  nano-specific  endpoints.  Controlled  human  studies  considering  exposure  data  are  needed  to  assess  the  validity  of
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health outcomes.  Validated  biomarkers  will  enable  the  progres
support the  implementation  of  consistent  occupational  limit  va
This  issue  of  particle  modification  and  the  subsequent
effects  this  may  have  on  toxicity/mode  of  action  creates
further  difficulties  in  isolating  truly  specific  biomarkers.
Taken  with  the  observation  that  there  is  no  step  change  in
toxicity  at  the  100  nm  nano-definition  threshold  and  little
support  for  truly  nano-specific  mode  of  action  in  toxicity,  it  is
evident  that  there  are  considerable  hurdles  in  nanoparticle-
specific  biomarkers.  Candidate  biomarkers  of  exposure
should  consider  the  unusual  properties  of  ENM  as  compared
to  chemicals,  such  as  the  ability  to  translocate  from  the
route  of  entry  or  perhaps  evade  uptake,  accumulate  in  dif-
ferent  regions  of  the  body,  or  change  their  chemical  identity
upon  the  interaction  with  biomolecules  [24].
Overall  it  is  evident  that  predicting  health  effects
resulting  from  exposure  to  ENM  is  difficult  due  to  their
heterogeneity  as  well  as  lack  of  available  tests.  Given
this  uncertainty,  a  complementary  approach  of  BM  in  high
exposure/risk  populations  (linked  with  exposure  monitoring)
could  provide  important  support  and  validation  of  labora-
tory  analysis  making  the  holistic  use  of  hypothesis  driven
laboratory  analysis  and  BM  a  pragmatic  solution.
Another  important  tool  is  systems  toxicology  (ST)  which
attempts  to  model  the  (patho)physiological  interactions
with  substances  using  computational  tools.  This  could  also
be  a  means  for  the  selection  of  biomarkers  by  provid-
ing  information  on  dynamic  interactions  with  ENM  and
by  assessing  whether  specific  biological  pathways  are
activated/perturbed  by  specific  ENM,  thus  identifying  nano-
specific  fingerprints  [25].
Due  to  the  impracticability  of  tracking  changes  in
the  chemical  identity  during  their  life-cycle,  the  RA  of
specific  nanoparticles  cannot  be  based  solely  on  laboratoryPlease  cite  this  article  in  press  as:  E.  
http://dx.doi.org/10.1016/j.nantod.2015.02.001
science  or  predictive  modelling,  but  should  be  supported  by
observational  studies  in  occupationally  exposed  workers.
Carrying  out  strictly  controlled  epidemiological  studies  is
recognized  as  the  main  requirement  for  the  assessment studies  aimed  at  assessing  their  predictivity  towards  relevant
of  knowledge  about  potential  risks  associated  to  ENM  and  will
as  a  key  component  of  an  effective  risks  management  system.
f  biomarker  validity  whilst  at  the  same  time  bridging
he  gap  between  laboratory  research  and  the  real  world
9,26]. From  epidemiological  data,  biologically  plausible
tatistical  associations  can  be  found  that,  taken  together
ith  experimental  data,  suggest  causation  or  simple
ssociation  between  exposure  and  health  effects.  Human
tudies,  although  ethically  sensitive,  are  needed  to  assess
he  validity  of  candidate  biomarkers  which  can  be  then
ssessed  for  their  ability  to  predict  health  effects.  These
alidated  biomarkers  will  advance  the  knowledge  about
otential  risks  associated  with  exposure  and  to  assess  the
ffectiveness  of  remediation  strategies  (e.g.  safety-by-
esign)  [22,27]. While  future  studies  should  address  the
nano)specificity  of  biomarkers,  the  priority  is  to  assess
hether  alteration  in  biomarker  baseline  values  occur  in
roups  of  exposed  workers  as  compared  to  a  control  group
nd  if  there  is  a  relationship  between  modification  of  the
iomarker(s)  and  adverse  human  health  effects.  Overall,
t  is  clear  that  biomarkers  and  biological  monitoring  need
o  be  used  widely  in  the  toolbox  of  nanosafety  to  support
aboratory  testing  and  risk  assessment.
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